ReviewFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Updates in Multiple Sclerosis Imaging.
Review in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS), one of the most common causes of neurological disability in young adults, is a chronic central nervous system disease characterized by immune-mediated inflammation, demyelination, and neurodegeneration. MS may be difficult to diagnose due to its protean neurological manifestations and the multitude of other neurologic conditions that can produce white matter lesions similar to MS demyelinating lesions. The wide clinical variability of the disease makes it challenging to provide an accurate prognosis in an individual with MS. Observations: Magnetic resonance imaging (MRI) biomarkers such as T2-lesions, chronic black holes, atrophy, paramagnetic rim lesions (PRL), and the central vein sign (CVS), may assist clinicians with the diagnosis and prognostication of MS. Underscoring their importance, PRL and CVS will be incorporated into the 2024 iteration of the McDonald Criteria for the diagnosis of MS. Quantitative MRI techniques, utilized in translational research, can quantify the degree of microstructural injury and guide the development of future therapies. This review discusses the impact, recent advances, and limitations of imaging biomarkers and quantitative MRI techniques with regard to routine MS clinical care and translational research. Conclusions: Clinicians caring for people with MS should have a basic understanding of imaging biomarkers and their implications for routine clinical care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.